This Blood Stem Cell Research Could Change Medicine of the Future
New discoveries about embryonic blood stem cell creation made independently by biomedical engineers and medical researchers at the University of New South Wales (UNSW) Sydney could one day eliminate the need for blood stem cell donors.
These achievements are part of a move in regenerative medicine towards the use of ‘induced pluripotent stem cells’ to treat disease. This is where stem cells are reverse engineered from adult tissue cells rather than using live human or animal embryos.
Although we have known about induced pluripotent stem cells since 2006, researchers still have plenty to learn about how cell differentiation in the human body can be mimicked artificially and safely in the lab for the purposes of delivering targeted medical treatment.
Induced pluripotent stem cells are a type of pluripotent stem cell that can be generated directly from a somatic cell. A somatic cell is any biological cell forming the body of a multicellular organism other than a gamete, germ cell, gametocyte, or undifferentiated stem cell.
UNSW researchers have recently completed two studies in this area that shine new light on not only how the precursors to blood stem cells occur in animals and humans, but how they may be induced artificially.
One study was published on September 13, 2022, in the journal Cell Reports by scientists from the UNSW School of Biomedical Engineering. They demonstrated how a simulation of an embryo’s beating heart using a microfluidic device in the lab led to the development of human blood stem cell ‘precursors’, which are stem cells on the verge of becoming blood stem cells.
In another article, which was recently published in Nature Cell Biology, researchers from UNSW Medicine & Health revealed the identity of cells in mice embryos responsible for blood stem cell creation.
Both studies are significant steps towards an understanding of how, when, where, and which cells are involved in the creation of blood stem cells. In the future, this knowledge could be used to help cancer patients, among others, who have undergone high doses of radio- and chemotherapy, to replenish their depleted blood stem cells.
Emulating the heart
In the study detailed in Cell Reports, lead author Dr. Jingjing Li and fellow researchers described how a 3cm x 3cm (1.2″ x 1.2″) microfluidic system pumped blood stem cells produced from an embryonic stem cell line to mimic an embryo’s beating heart and conditions of blood circulation.
She said that in the last few decades, biomedical engineers have been trying to make blood stem cells in laboratory dishes to solve the problem of donor blood stem cell shortages. But no one has yet been able to achieve it.
“Part of the problem is that we still don’t fully understand all the processes going on in the microenvironment during embryonic development that leads to the creation of blood stem cells at about day 32 in the embryonic development,” Dr. Li said.
“So we made a device mimicking the heart beating and the blood circulation and an orbital shaking system which causes shear stress – or friction – of the blood cells as they move through the device or around in a dish.”
These systems promoted the development of precursor blood stem cells which can differentiate into various blood components – white blood cells, red blood cells, platelets, and others. They were excited to see this same process – known as hematopoiesis – replicated in the device.
Study co-author Associate Professor Robert Nordon said he was amazed that not only did the device create blood stem cell precursors that went on to produce differentiated blood cells, but it also created the tissue cells of the embryonic heart environment that is crucial to this process.
“The thing that just wows me about this is that blood stem cells, when they form in the embryo, form in the wall of the main vessel called the aorta. And they basically pop out of this aorta and go into the circulation, and then go to the liver and form what’s called definitive hematopoiesis, or definitive blood formation.
“Getting an aorta to form and then the cells actually emerging from that aorta into the circulation, that is the crucial step required for generating these cells.”
“What we’ve shown is that we can generate a cell that can form all the different types of blood cells. We’ve also shown that it is very closely related to the cells lining the aorta – so we know its origin is correct – and that it proliferates,” A/Prof. Nordon said.
The researchers are cautiously optimistic about their achievement in emulating embryonic heart conditions with a mechanical device. They hope it could be a step towards solving challenges limiting regenerative medical treatments today: donor blood stem cell shortages, rejection of donor tissue cells, and the ethical issues surrounding the use of IVF embryos.
“Blood stem cells used in transplantation require donors with the same tissue type as the patient,” A/Prof. Nordon said.
“Manufacture of blood stem cells from pluripotent stem cell lines would solve this problem without the need for tissue-matched donors providing a plentiful supply to treat blood cancers or genetic disease.”
Dr. Li added: “We are working on up-scaling manufacture of these cells using bioreactors.”
Meanwhile, and working independently of Dr. Li and A/Prof. Nordon, UNSW Medicine & Health’s Professor John Pimanda and Dr. Vashe Chandrakanthan were doing their own research into how blood stem cells are created in embryos.
In their study of mice, the researchers looked for the mechanism that is used naturally in mammals to make blood stem cells from the cells that line blood vessels, known as endothelial cells.
“It was already known that this process takes place in mammalian embryos where endothelial cells that line the aorta change into blood cells during hematopoiesis,” Prof. Pimanda said.
“But the identity of the cells that regulate this process had up until now been a mystery.”
In their paper, Prof. Pimanda and Dr. Chandrakanthan described how they solved this puzzle by identifying the cells in the embryo that can convert both embryonic and adult endothelial cells into blood cells. The cells – known as ‘Mesp1-derived PDGFRA+ stromal cells’ — reside underneath the aorta, and only surround the aorta in a very narrow window during embryonic development.
Dr. Chandrakanthan said that knowing the identity of these cells provides medical researchers with clues on how mammalian adult endothelial cells could be triggered to create blood stem cells – something they are normally unable to do.
“Our research showed that when endothelial cells from the embryo or the adult are mixed with ‘Mesp1 derived PDGFRA+ stromal cells’ – they start making blood stem cells,” he said.
While more research is needed before this can be translated into clinical practice – including confirming the results in human cells – the discovery could provide a potential new tool to generate engraftable hematopoietic cells.
“Using your own cells to generate blood stem cells could eliminate the need for donor blood transfusions or stem cell transplantation. Unlocking mechanisms used by Nature brings us a step closer to achieving this goal,” Prof. Pimanda said.
“Mimicry of embryonic circulation enhances the hoxa hemogenic niche and human blood development” by Jingjing Li, Osmond Lao, Freya F. Bruveris, Liyuan Wang, Kajal Chaudry, Ziqi Yang, Nona Farbehi, Elizabeth S. Ng, Edouard G. Stanley, Richard P. Harvey, Andrew G. Elefanty and Robert E. Nordon, 13 September 2022, Cell Reports.DOI: 10.1016/j.celrep.2022.111339
“Mesoderm-derived PDGFRA+ cells regulate the emergence of hematopoietic stem cells in the dorsal aorta” by Vashe Chandrakanthan, Prunella Rorimpandey, Fabio Zanini, Diego Chacon, Jake Olivier, Swapna Joshi, Young Chan Kang, Kathy Knezevic, Yizhou Huang, Qiao Qiao, Rema A. Oliver, Ashwin Unnikrishnan, Daniel R. Carter, Brendan Lee, Chris Brownlee, Carl Power, Robert Brink, Simon Mendez-Ferrer, Grigori Enikolopov, William Walsh, Berthold Göttgens, Samir Taoudi, Dominik Beck and John E. Pimanda, 28 July 2022, Nature Cell Biology.DOI: 10.1038/s41556-022-00955-3
Funding: National Health and Medical Research Council, Stem Cells Australia, Stafford Fox Medical Research Foundation, Novo Nordisk